INZY Form 4: 4.5 M Shares Tendered at $4 After BioMarin Merger

Q: What did Form 4 for INZY dated 07/01/2025 report?

It reported that director Robert L. Hopfner tendered about 4.49 million INZY shares for $4.00 cash per share under BioMarin鈥檚 merger.

Q: How many Inozyme shares were disposed of in the filing?

Pivotal bioVenture Partners Fund I disposed of 2,923,110 shares and Fund II disposed of 1,571,741 , totaling 4,494,851 shares.

Q: What consideration did INZY shareholders receive in the merger?

Each common share was exchanged for $4.00 in cash , without interest, subject to tax withholding.

Q: When did the BioMarin鈥揑nozyme merger become effective?

The merger closed on 1 July 2025 , when Incline Merger Sub merged into Inozyme.

Q: Is INZY still publicly traded after 1 July 2025?

No. Inozyme became a wholly-owned subsidiary of BioMarin , ending its status as an independent public company.

[Form 4] Snowflake Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Form 4 Overview 鈥� Inozyme Pharma, Inc. (INZY)

This Form 4 discloses that Robert L. Hopfner, a director of Inozyme Pharma and managing partner of Pivotal bioVenture Partners, disposed of his indirect holdings in the company on 1 July 2025 as a result of Inozyme鈥檚 acquisition by BioMarin Pharmaceutical Inc.

Transaction structure: The shares were tendered pursuant to the Agreement and Plan of Merger dated 16 May 2025 between Inozyme, BioMarin and Incline Merger Sub.
Consideration: All common shares were exchanged for $4.00 cash per share (the 鈥淢erger Consideration鈥�), without interest and subject to tax withholding.
Holdings affected:
- Pivotal bioVenture Partners Fund I, L.P. 鈥� 2,923,110 shares
- Pivotal bioVenture Partners Fund II, L.P. 鈥� 1,571,741 shares
Total indirect disposition: 4,494,851 shares.
Post-merger status: Effective 1 July 2025, Incline Merger Sub merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin.

No derivative securities were reported. The filing is made by one reporting person and executed by power of attorney.

Positive

Completion of merger at $4.00 per share provides definitive cash exit for shareholders.
Large insider positions (鈮�4.5 M shares) successfully tendered, confirming deal execution without holdouts.

Negative

Public float eliminated; investors seeking ongoing exposure to Inozyme鈥檚 pipeline must now own BioMarin shares, not INZY.

Insights

TL;DR: Filing shows cash-out of 4.5 M shares at $4 via BioMarin merger; confirms deal close and shareholder liquidity.

The Form 4 is strictly confirmatory: it documents the automatic tender of Pivotal-controlled shares when BioMarin鈥檚 offer became effective. The $4.00 per-share price, already agreed in May, is now consummated, demonstrating completion of the acquisition and extinguishment of public equity. For investors, the key takeaway is that all public shareholders鈥攊ncluding large VC holders鈥攈ave received the same cash consideration, closing the transaction. There is no new valuation information beyond the stated consideration, but the filing eliminates any residual execution risk surrounding the merger.

TL;DR: Insider filing confirms exit; INZY no longer an independent investable equity post 1 July 2025.

From a portfolio perspective, the event converts equity exposure to cash at $4.00 per share. Investors holding INZY should already have been tendered or will receive cash shortly; the stock will be delisted or stopped trading. There is no incremental upside or downside signalled here鈥攐nly confirmation that the liquidity event closed. Any residual positions in trading systems should be reconciled and removed.

07/03/2025 - 06:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Briggs Teresa

(Last)

(First)

(Middle)

C/O SNOWFLAKE INC.

106 EAST BABCOCK STREET, SUITE 3A

(Street)

BOZEMAN

59715

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Snowflake Inc. [ SNOW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/02/2025		A		1,373⁽¹⁾	A	$0	5,620⁽²⁾	D
Common Stock	07/03/2025		S⁽³⁾		1,146	D	$217.74	4,474⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares represent restricted stock units, which will vest in full on the earlier of (i) the date of the annual meeting of the Issuer's stockholders to be held in 2026 (or the date immediately prior to such meeting if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election), or (ii) the first anniversary of the date of grant; subject to the Reporting Person's continued service through such date.

2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.

3. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025.

Remarks:

	/s/ Marie Reider, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Form 4 for INZY dated 07/01/2025 report?

It reported that director Robert L. Hopfner tendered about 4.49 million INZY shares for $4.00 cash per share under BioMarin鈥檚 merger.

How many Inozyme shares were disposed of in the filing?

Pivotal bioVenture Partners Fund I disposed of 2,923,110 shares and Fund II disposed of 1,571,741, totaling 4,494,851 shares.

What consideration did INZY shareholders receive in the merger?

Each common share was exchanged for $4.00 in cash, without interest, subject to tax withholding.

When did the BioMarin鈥揑nozyme merger become effective?

The merger closed on 1 July 2025, when Incline Merger Sub merged into Inozyme.

Is INZY still publicly traded after 1 July 2025?

No. Inozyme became a wholly-owned subsidiary of BioMarin, ending its status as an independent public company.

AG真人官方

[Form 4] Snowflake Inc. Insider Trading Activity

Insights

FAQ

What did Form 4 for INZY dated 07/01/2025 report?

How many Inozyme shares were disposed of in the filing?

What consideration did INZY shareholders receive in the merger?

When did the BioMarin鈥揑nozyme merger become effective?

Is INZY still publicly traded after 1 July 2025?

NYSE:SNOW

SNOW Rankings

SNOW Latest News

SNOW Latest SEC Filings

SNOW Stock Data

AG真人官方

Trending News

[Form 4] Snowflake Inc. Insider Trading Activity

Insights

M&A Specialist positive

Portfolio Manager neutral

FAQ

What did Form 4 for INZY dated 07/01/2025 report?

How many Inozyme shares were disposed of in the filing?

What consideration did INZY shareholders receive in the merger?

When did the BioMarin鈥揑nozyme merger become effective?

Is INZY still publicly traded after 1 July 2025?

NYSE:SNOW

SNOW Rankings

SNOW Latest News

SNOW Latest SEC Filings

SNOW Stock Data